Managing Opioid-Tolerant Patients in the Perioperative Surgical Home

John T. Wenzel, MD*, Eric S. Schwenk, MD, Jaime L. Baratta, MD, Eugene R. Viscusi, MD

INTRODUCTION

Acute pain is a major concern of many patients preparing to undergo surgery. The incidence of postoperative acute pain varies widely in the literature. It has been reported as high as 80% and is likely underreported.1 Such data suggest that uncontrolled acute postoperative pain continues to be an unmet need and a target for improvement. This is further compounded in opioid-tolerant patients receiving chronic opioids at baseline. While preparing to manage opioid-tolerant patients, mechanisms underlying chronic postsurgical pain (CPSP), acute opioid tolerance, and opioid-induced hyperalgesia (OIH) are poorly understood but highly relevant. The emerging model of the perioperative surgical home (PSH) puts anesthesiologists in position to best

KEYWORDS

• Opioid tolerance • Multimodal analgesia • Perioperative surgical home • Buprenorphine

KEY POINTS

• In the perioperative surgical home model, anesthesiologists are well positioned to manage complex patients, including those who are opioid-tolerant, because of their training and expertise in pharmacology.

• Opioid-tolerant patients present challenges for postoperative analgesia, posing dual risks of poor pain control and medication-related toxicity.

• Reduction of opioids through regional anesthesia techniques and multimodal nonopioid agents can improve analgesia and minimize opioid-related complications in the high-risk opioid-tolerant population.

INTRODUCTION

Acute pain is a major concern of many patients preparing to undergo surgery. The incidence of postoperative acute pain varies widely in the literature. It has been reported as high as 80% and is likely underreported.1 Such data suggest that uncontrolled acute postoperative pain continues to be an unmet need and a target for improvement. This is further compounded in opioid-tolerant patients receiving chronic opioids at baseline. While preparing to manage opioid-tolerant patients, mechanisms underlying chronic postsurgical pain (CPSP), acute opioid tolerance, and opioid-induced hyperalgesia (OIH) are poorly understood but highly relevant. The emerging model of the perioperative surgical home (PSH) puts anesthesiologists in position to best
address complicated patients, particularly those with preexisting chronic pain conditions and who are opioid tolerant as a result of chronic opioid therapy.

**The Perioperative Surgical Home**

The PSH has been supported by the American Society of Anesthesiologists (ASA) to improve outcomes while improving efficiency, broadening the role of the anesthesiologist in preoperative, intraoperative, and postoperative care. It is defined by the ASA as “a patient-centered and physician-led multidisciplinary and team-based system of coordinated care that guides the patient throughout the entire surgical experience.” The Triple Aim goals of the PSH as described by Berwick and colleagues include

1. Improving the individual experience of care
2. Improving the health of populations
3. Reducing the per capita cost of care

The PSH for surgical patients has been compared with the patient-centered medical home (PCMH) for primary care. Recent data suggest that the PCMH improves outcomes and reduces costs. Development of the PSH requires the support of hospital administration and collaboration of surgeons and anesthesiologists. Anesthesiologists are particularly well suited to staff the PSH as the physician team leader. Because many institutions do not have an existing preoperative anesthesia clinic, development of a PSH can be financially challenging. If there is institutional support or desire for PSH development, the institution and anesthesia practice need to be financially aligned with an agreement to support funding. Compensation for staffing also needs to be considered. Hospital administration may be willing to compensate anesthesiologists for this practice if a financial benefit can be demonstrated. Reimbursement for anesthesiologists may mirror that of internists in the PCMH, as the Centers for Medicare and Medicaid Services have recognized the value of the PCMH. Future payment models that include bundled payments for services may make anesthesiologist compensation complicated.

Once the PSH is implemented, services begin with early patient engagement after the decision for surgery is made. The surgical experience is treated as a fluid continuum rather than discrete presurgical, intrasurgical, and postsurgical phases. It involves appropriate risk stratification and preoperative testing, decreased redundancy in testing, improved operating room efficiency, decreased variability through the use of evidence-based surgical care pathways, and postsurgical care initiatives. The authors focus on management of opioid-tolerant patients within the PSH.

**Opioids**

Opioids remain a mainstay of analgesia regimens for surgical patients. Prescriptions for opioids as well as the increased incidence of prescription opioid abuse have been increasing in recent years, especially in the United States and Canada. Opioid-related deaths and adverse events have seen a similar spike. Yet, despite the increased use of opioid medications to manage pain and improve function, there remains a serious and significant mismatch between the number of prescriptions issued and positive end outcomes of pain care in the United States. In some patients, chronic opioid exposure, especially at high doses, has been attributed to a progressive reduction in analgesia while increasing risks of opioid tolerance, opioid-induced hyperalgesia, and medication misuse. These issues come into focus when patients on chronic opioid therapy have indications for surgery.
**Opioid Tolerance**

- It is a phenomenon whereby increasing opioid doses are required for analgesia because of a desensitization of pain signaling at the opioid receptor.\(^9\)
- Acute opioid tolerance may develop rapidly in patients who are opioid-naïve.\(^10\)
- Patients exposed to high intraoperative opioid doses have demonstrated increased postoperative pain and opioid requirements.
- These higher opioid doses are associated with an increased risk of adverse events.\(^9\)

**Opioid-Induced Hyperalgesia**

- OIH is nociceptive sensitization likely caused by neuroplastic changes in the central and peripheral nervous systems caused by opioid exposure, leading to paradoxical worsening of pain with increasing opioid doses.
- Remifentanil has been particularly implicated; but it may occur with acute or chronic exposure, high or low doses, and any opioid or route of administration.\(^11\)
- Prevalence of OIH is likely underappreciated as its diagnosis can be very challenging and it can be confused with tolerance, worsening disease, or even opioid withdrawal.
- When OIH is suspected, opioid dose reduction may improve analgesia. Other proposed treatments include opioid rotation, N-methyl-D-aspartate (NMDA) receptor antagonists (ketamine, memantine, dextromethorphan), interventional pain management, or behavioral management.\(^11\)
- Rotation to methadone is of particular interest because it is both a mu-receptor opioid agonist and an NMDA-receptor antagonist.

Managing acute postoperative pain may be especially challenging in opioid-tolerant patients; increasing doses of opioids to overcome tolerance is a poor management strategy, as this may result in unwanted opioid side effects, including sedation, respiratory depression, ileus, and paradoxical worsening of pain. Multimodal analgesia involves the incorporation of several medications with unique mechanisms of action in an effort to improve analgesia and minimize the side effects of any one class of medication, especially opioids. These patients may benefit the most from preoperative optimization of their pain regimen, context-appropriate selection of intraoperative anesthetic techniques, and a multimodal postoperative analgesic plan.

**PREOPERATIVE ASSESSMENT**

In the PSH, the preoperative assessment begins in the preoperative clinic rather than at the bedside on the day of surgery. Patients often encounter their anesthesiologist for the first time in the presurgery holding area minutes before surgery, whereas a previously scheduled comprehensive assessment in the clinic affords time to enact a management plan for opioid-tolerant patients. This anticipatory planning and care coordination also creates the opportunity to provide perioperative education, to set expectations, and alleviate patient anxiety. Managing patient expectations for pain management is critical to success and enhances patient satisfaction. Both surgeon and anesthesiologist should be attuned to early identification and management of opioid-tolerant patients.

Assessment begins with a thorough history and physical examination and includes elucidation of the location and nature of chronic pain as well as the degree of functional impairment. Particular attention should be paid to patients’ current pain regimen, including exact doses, schedule, routes of administration, prescriber, and effects (positive and negative). A complete history includes past medication use and experiences (Box 1). Patients who cannot provide evidence of accountability for their
opioids justify additional exploration into opioid abuse, misuse, or diversion. A urine drug screen may be useful to determine potential substance misuse, abuse, or diversion. In the face of active, undiagnosed substance abuse, a joint decision between the surgeon and anesthesiologist should be made, weighing the risks of the abuse on both the patients’ current health and surgical outcome. A more detailed discussion of substance abuse is out of the scope of this article.

The nature of the proposed surgery is important in determining the anesthetic and analgesic plan. Is it major surgery requiring hospital admission with high levels of anticipated pain? On the other hand, is discharge home on the same day anticipated? Is the procedure and medical circumstances of patients suitable for a regional anesthetic technique? Would any drugs or techniques be contraindicated because of patient characteristics (eg, renal or liver disease) or surgical type (eg, positioning, bleeding risk, or bone healing)?

Taking into account patients’ medical history, planned surgery, current therapies, and existing and anticipated pain, the anesthesiologist may tailor a specific anesthetic plan that involves a combination of preemptive analgesia, regional techniques, intraoperative agents, and postoperative multimodal analgesia. Multimodal regimens are especially important for opioid-tolerant patients, with the goals of adequate analgesia, prevention of CPSP, and minimization of opioids and their associated adverse events. Chronic exposure to opioids reduces drug efficacy, requiring increasing doses to achieve similar analgesic effects. These patients may be at an increased risk when compared with opioid-naïve patients, whereby increasing dosages to improve efficacy increases the risk of adverse events, most significantly respiratory depression. Additionally, opioid-tolerant patients presenting for surgery may have altered pain sensitivity that includes generalized hyperalgesia or ill-defined pain remote to the surgical site. We are, therefore, left to maximize the utility of nonopioid agents and regional techniques.

The advantages of a patient-specific analgesic plan are several-fold: first, patients will be well informed about expectations and will not be expected to make decisions about their care immediately before or after surgery when they are likely to be in a more anxious, distressed, or cognitively impaired state from sedatives or anesthetics. From an ethical standpoint, this is important with regard to adequacy of informed consent. Second, communication is improved with the intraoperative anesthesia team when there is sufficient time for concerns of all parties to be elicited, discussed, and clarified. Finally, this early encounter and assessment affords time to prepare for and enact management plans for specific therapies.

<table>
<thead>
<tr>
<th>Box 1 Components of the preoperative assessment for opioid-tolerant patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Clarification of preexisting pain and functional limitations</td>
</tr>
<tr>
<td>• Current opioid medications, including dose, frequency, and any changes in dose in the past 6 months</td>
</tr>
<tr>
<td>• Current opioid prescriber and dispensing pharmacy</td>
</tr>
<tr>
<td>• Current nonopioid analgesics (eg, acetaminophen, nonsteroidal antiinflammatory drugs, cyclooxygenase-2 inhibitors, antineuropathic agents, benzodiazepines, muscle relaxants)</td>
</tr>
<tr>
<td>• Past opioid medications and their effectiveness and tolerability of side effect profile</td>
</tr>
<tr>
<td>• Review of potential misuse or abuse of opioids</td>
</tr>
<tr>
<td>• Discussion of expectations and anticipated level of pain associated with the particular procedure (mild, moderate, severe), including perceptions from past surgical experiences</td>
</tr>
</tbody>
</table>

Wenzel et al
Opioid Agonists

The anesthesiologist must first determine which patients require extra attention and should be considered opioid tolerant. Tolerance is defined by the Food and Drug Administration (FDA) as the use of greater than or equal to 60 mg of oral morphine equivalents per day for 7 days or longer, regardless of long-term opioid use. Opioid-tolerant patients may be taking a variety of opioids at home in immediate-release, short-acting (e.g., oxycodone, hydrocodone, morphine, oral transmucosal fentanyl) or extended-release, long-acting (e.g., morphine sulfate [MS Contin], oxycodone hydrochloride [OxyContin], transdermal fentanyl patch) preparations. Routes of administration may include oral, subcutaneous, transdermal, or intrathecal delivery. Patients should be advised to continue their usual analgesic regimen, including regularly scheduled immediate- or extended-release and transdermal agents.

Methadone is a mu-receptor opioid agonist that may be prescribed for the treatment of chronic pain or as a once-daily opioid replacement therapy for addiction. These patients have tolerance to opioids but may also have increased pain sensitivity. Patients on methadone for both chronic pain or methadone maintenance therapy should continue their scheduled regimen perioperatively to avoid fluctuations in methadone levels given its long half-life.

An evidence-based multimodal analgesic plan is necessary for opioid-tolerant patients to provide adequate analgesia and prevent withdrawal but also to reduce the length of hospital stay and prevent occurrences of readmission. Despite the FDA definition of tolerance, in clinical acute pain practice, chronic use of relatively low levels of daily opioid exposure (20 mg morphine equivalents daily for greater than 7–10 days) can significantly reduce the effectiveness of postoperative opioids, leading to poorly controlled pain.

The specific components of any multimodal analgesic plan will vary based on specific patient and surgical factors, but includes regional or neuraxial anesthesia/analgesia when possible, nonopioid adjunct agents (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs]/cyclooxygenase-2 [COX-2] inhibitors, acetaminophen, gabapentinoids, alpha-agonists, intravenous [IV] lidocaine), and NMDA-receptor antagonists (e.g., ketamine), using opioids for rescue analgesia only. Preoperative dosing of nonopioid analgesics is gaining popularity and typically involves medications taken before surgery and continued around-the-clock postoperatively (Table 1). Pregabalin, gabapentin, and celecoxib have demonstrated benefit when started preoperatively in reducing the need for postoperative opioids. The combination of acetaminophen, pregabalin, and celecoxib has shown benefit when started preoperatively and continued around-the-clock postoperatively.

At the authors’ institution, this has been adopted for orthopedic, urologic, and gynecologic procedures.

Table 1
Multimodal nonopioid agents for preemptive analgesia

<table>
<thead>
<tr>
<th>Drug</th>
<th>Administration Route</th>
<th>Suggested Dose (2 h Before Surgery)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen</td>
<td>PO</td>
<td>1000 mg (more than 50 kg)</td>
</tr>
<tr>
<td>Celecoxib</td>
<td>PO</td>
<td>200–400 mg</td>
</tr>
<tr>
<td>Pregabalin</td>
<td>PO</td>
<td>75–150 mg</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>PO</td>
<td>900–1200 mg</td>
</tr>
</tbody>
</table>

Downloaded from ClinicalKey.com at Maimonides Medical Center - JC October 19, 2016. For personal use only. No other uses without permission. Copyright ©2016. Elsevier Inc. All rights reserved.
INTRAOPERATIVE MANAGEMENT

In the PSH model, the anesthesiologist caring for patients on the day of surgery will have the advantage of the thorough preoperative assessment and management strategy already in place. The anesthesiologist can then advise patients of the finalized anesthetic plan. Patients should continue their analgesic regimen up until the time of surgery, including any morning doses of opioid.

While tailoring the analgesic plan, the anesthesiologist must also take into account the nature of patients' pain and the mechanisms of analgesic agents to be used. Pain is complex and subjective; there are 5 generally recognized categories of pain: nociceptive, neuropathic, psychogenic, mixed, and idiopathic:

- Nociceptive pain can be described as sharp or dull, aching, throbbing, pressure-like, or feelings of stiffness.
- Neuropathic pain is often burning, shocklike tingling, or stabbing.
- Mixed pain is a result of stimulation of both nociceptive and neuropathic pathways.
- Psychogenic pain is pain that is thought to be an emotional or psychiatric phenomenon, only to be considered once all other nociceptive or neuropathic causes have been ruled out.
- Idiopathic pain is due to unknown origin.

The concept of multimodal analgesia takes into account understanding the type of pain in need of treatment and targeting it at multiple sites along the pain pathway to achieve a synergistic effect with different classes of analgesics.

- Opioids act both supraspinally via inhibitory pathways as well as in the dorsal horn to impede nociception.
- NSAIDs act both in the spinal cord and periphery, inhibiting cyclooxygenase to decrease inflammation secondary to prostaglandins and further decrease nociception.
- Acetaminophen acts centrally likely via inhibition of cyclooxygenase in treating nociceptive pain.
- Local anesthetics act at central, spinal, and peripheral sites, depending on route or localization of administration.
- NMDA receptor antagonists, exerting effects in the dorsal horn, inhibit nociceptive and neuropathic pain.
- Gabapentinoids bind to calcium channels in the spinal cord and brain to decrease neuropathic pain.

Although opioid-tolerant patients presenting for surgery will need opioids perioperatively, multimodal pain regimens are paramount in managing acute surgical pain in these cases. These regimens may include the use of intraoperative adjuncts, such as epidural/regional analgesia, ketamine, dexmedetomidine, and lidocaine infusions.

Ketamine

A single dose of opioid will lead to activation of NMDA receptors. In theory, tolerance and hyperalgesia begins with the first dose of an opioid. In animal studies, ketamine, an NMDA-receptor antagonist, reversed morphine tolerance and improved effectiveness while additionally preventing acute tolerance. The use of ketamine as an analgesic adjunct in opioid-naïve patients resulted in decreased opioid requirements after surgery; fewer opioid-related side effects, such as nausea and vomiting; and possibly...
prevention of chronic pain and hyperalgesia. Few studies, however, have examined the effect of intraoperative ketamine in opioid-tolerant patients.

A study by Loftus and colleagues showed that intraoperative ketamine infusions resulted in reduced opioid requirements in the first 48 hours and at 6 weeks postoperatively in opioid-dependent patients undergoing back surgery. Additionally, average pain scores were significantly reduced in the postanesthesia care unit (PACU) and at 6 weeks postoperatively. The investigators recommended patients taking 30 mg or more per day of morphine equivalents with expected moderate-severe postsurgical pain receive a bolus of ketamine of 0.5 mg/kg followed by infusion of 0.25 mg/kg/h intraoperatively.

Postoperatively, ketamine infusions may be safely administered without continuous cardiac or respiratory monitoring (intensive care unit or telemetry). An in-house acute pain management service (APMS) team is crucial to provide regular monitoring of analgesia and titration. Although studies demonstrate that it is well tolerated, patients should be monitored for neurologic and psychological side effects.

Regional Anesthesia and Analgesia

Several surgical procedures, including extremity surgery, carotid endarterectomy, and hernia repair, may be done under a regional/neuraxial block as the sole anesthetic, thus decreasing the reliance of opioids in opioid-tolerant patients.

Although general anesthesia is often indicated, regional analgesia as part of a multimodal regimen decreases opioid burden in these challenging patients. The use of long-acting local anesthetics and continuous catheters enable regional analgesia to be effective during the first few days following surgery when acute pain is most severe.

Utilization of perineural catheters results in prolonged postoperative pain control (including resting and dynamic pain), accelerated resumption of therapy, less reliance on opioids, fewer sleep disturbances, and overall increased patient satisfaction. Epidural analgesia results in improved rehabilitation, better pain control, and decreased opioid consumption when compared with opioids alone.

Appropriate regional techniques, including single-shot or continuous peripheral nerve blocks or epidural analgesia, should be used whenever possible. Although regional anesthesia offers many benefits in opioid-tolerant patients, opioids must be judiciously continued to prevent withdrawal and to treat the chronic pain not related to the surgical procedure.

Lidocaine Infusions

The use of an IV lidocaine infusion has been widely studied in abdominal surgery. In open and laparoscopic abdominal surgery, an IV lidocaine infusion resulted in decreased postoperative pain for 48 hours postoperatively, reduced opioid consumption, earlier return of bowel function, earlier rehabilitation, and decreased length of stay.

When compared with thoracic epidural analgesia in patients undergoing colorectal surgery, intraoperative and postoperative lidocaine infusions resulted in similar times to return of bowel function and time to discharge; however, epidural analgesia resulted in lower numeric pain scores.

The benefit of intraoperative lidocaine infusions may not apply to all types of surgery as the addition of lidocaine in patients undergoing mastectomy did not result in decreased pain or reduced opioid consumption when compared with placebo. Although the use of intraoperative lidocaine infusions has not been well studied in the opioid-tolerant population, current literature suggests it may be useful as part of a multimodal regimen when regional techniques are contraindicated. A common dosing strategy is a 1.5-mg/kg loading dose followed by 1.5 mg/kg/h intraoperatively.
**Dexmedetomidine**

With the high density of receptors in the dorsal horn, alpha-2 adrenergic agonists act on the central nervous system to reduce pain. Dexmedetomidine is a highly selective alpha-2 agonist that acts as a sedative, anxiolytic, sympatholytic, and analgesic with minimal respiratory depression.

In rats with presumed neuropathic pain, dexmedetomidine exhibited antihyperalgesic action. In patients undergoing laparoscopic bariatric surgery, randomized to receive 0.2, 0.4, or 0.8 mcg/kg/h dexmedetomidine infusion intraoperatively, dexmedetomidine decreased opioid use, need for antiemetic treatment, and length of stay in the PACU but did not change opioid use patterns or quality of recovery beyond the PACU.

Given the cardiovascular effects of dexmedetomidine infusions, namely, bradycardia and hypotension, Tufanogullari and colleagues recommended a 0.2-mcg/kg/h infusion intraoperatively as an analgesic adjunct. Gurbet and colleagues showed an intraoperative dexmedetomidine rate of 0.5 mcg/kg/h decreased 48-hour opioid consumption with no change in pain scores following total abdominal hysterectomy when compared with placebo. Although dexmedetomidine has not been specifically studied in the opioid-tolerant population, the literature suggests a continuous infusion during surgery may decrease intraoperative opioid requirements. It is likely that continuation of dexmedetomidine is necessary to extend opioid reduction beyond the PACU.

**POSTOPERATIVE MANAGEMENT**

The care of opioid-tolerant patients continues well beyond the operating room and into the PACU as part of the PSH model. Although the surgeon typically orders analgesics for the patients when on the medical ward, there is substantial opportunity for input and collaboration by the anesthesiologist. Medication management and expectations for postoperative analgesia can be established early on and can help create a positive patient experience.

In this section, strategies to managing postoperative analgesia for opioid-tolerant patients are discussed, including

- Benefits of a nonopioid multimodal approach
- Resuming home medications, including opioid agonist-antagonists
- The role of acute pain services in the PSH model

**Multimodal Approach to Postoperative Analgesia**

Inadequate postoperative pain management has been linked with complications, including myocardial ischemia, impaired pulmonary function, ileus, thromboembolism, impaired immune function, wound infection, and anxiety. Additionally, hospital reimbursements are now linked to patient satisfaction scores (Hospital Consumer Assessment of Healthcare Providers and Systems [HCAHPS]). Pain is a significant driver of poor patient satisfaction. Poor outcomes related to uncontrolled pain result in greater health care costs.

Multimodal analgesia has been successfully implemented into multiple surgical pathways, and has been shown to reduce opioid consumption, surgical complications, and length of hospital stay. Some agents that have been used successfully in multimodal pathways include acetaminophen (by mouth and IV), COX-2 inhibitors, gabapentinoids ( gabapentin and pregabalin), NSAIDs, glucocorticoids, local anesthetics, α-2 agonists (clonidine and dexmedetomidine), and ketamine (Table 2). To the extent possible, these agents can be used to minimize opioids and improve analgesia.
Multimodal analgesia pathways have existed for more than 15 years; but Kehlet and colleagues were the first to describe pathways leading to clinically important outcomes, such as reduction in length of hospital stay in colorectal procedures. There have been several large reviews and meta-analyses summarizing the literature on several multimodal agents, with both gabapentin and pregabalin demonstrating an opioid-reducing effect when used in a multimodal pathway. The addition of an NSAID to an opioid as part of a multimodal pathway provides better analgesia than the opioid alone. Taken together, these studies provide evidence that using nonopioid agents whenever possible can improve analgesia; this is even more so for opioid-tolerant patients.

Because the doses of opioids taken chronically by the opioid-tolerant population often exceed many physicians’ comfort levels, surgeons frequently seek recommendations on discharge regimens. Conversion from IV to oral opioids requires experience and expertise of a physician experienced in pain management.

**Postoperative Oral Analgesics and Restarting Home Medications**

If patients were taking a combination opioid preoperatively (eg, hydrocodone/acetaminophen), that creates an opportunity for the anesthesiologist to initiate a discussion with the surgeon about postoperative analgesics. Nonopioid adjuncts, such as acetaminophen, NSAIDs, and gabapentinoids, should be initiated as the mainstay of treatment, with opioids for breakthrough pain only. Unless patients underwent gastrointestinal surgery or cannot take anything by mouth for other reasons, oral medications may be started on the evening of the day of surgery. However, for patients admitted to the hospital after painful surgery, IV opioids are often needed. Opioids delivered via IV patient-controlled analgesia (PCA) lead to better patient satisfaction than intermittent boluses given via oral, intramuscular, or IV routes as well as lower rates of adverse events. More potent opioids, such as hydromorphone or sufentanil, may be considered when treating opioid-tolerant patients. Higher-dose PCA settings may be needed to deliver adequate analgesia.

**SPECIAL CONSIDERATIONS: OPIOID ADDICTION THERAPY**

Patients treated for opioid addiction present a particular challenge in that many have a history of longstanding opioid abuse with significant tolerance and hyperalgesia. It is not unusual for patients in recovery to be exceedingly fearful of exposure to nonmaintenance opioids if they are on such a regimen, or reexposure to opioids if they have managed to be fully abstinent. In addition to the opioid agonist methadone, patients being treated with opioid-replacement therapy (ORT) may be maintained on

---

**Table 2**

**Multimodal nonopioid agents for postoperative analgesia**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Administration Route</th>
<th>Suggested Dose and Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen</td>
<td>PO/IV</td>
<td>1000 mg q 6 h (more than 50 kg)</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>PO</td>
<td>600 mg q 6 h</td>
</tr>
<tr>
<td>Ketorolac</td>
<td>PO/IV</td>
<td>15–30 mg q 6 h</td>
</tr>
<tr>
<td>Celecoxib</td>
<td>PO</td>
<td>200–400 mg q 12 h</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>PO</td>
<td>600–800 mg TID</td>
</tr>
<tr>
<td>Pregabalin</td>
<td>PO</td>
<td>75–150 mg q 12 h</td>
</tr>
<tr>
<td>Ketamine</td>
<td>IV</td>
<td>0.5 mg/kg bolus; infusion 0.25 mg/kg/h</td>
</tr>
</tbody>
</table>
buprenorphine (categorized as a partial agonist, although its pharmacology is debated) or an opioid antagonist (naltrexone), each with unique considerations.

**Buprenorphine**

Buprenorphine is a semisynthetic opioid with a high mu-receptor binding affinity. It is marketed as a sole agent (Subutex) or in combination with naloxone (Suboxone) to deter abuse. A transbuccal patch delivery form of buprenorphine has been recently approved by the FDA for the treatment of chronic pain. There are limited data to guide perioperative management of patients taking buprenorphine; furthermore, its high binding affinity, slow dissociation, and analgesic ceiling effect may make adequate analgesia a challenge.

Analgesic strategies for patients on buprenorphine mainly stem from expert opinion and case reports. Bryson describes 2 basic treatment options as continuing buprenorphine throughout the perioperative period or stopping buprenorphine before surgery.

There is no clear consensus on the best strategy for managing buprenorphine preoperatively, with many recommending it be stopped preoperatively to avoid the analgesic ceiling effect of buprenorphine or the high dose of supplemental opioids that may be required. Discontinuation of ORT, however, carries a risk of relapse that will need to be evaluated on an individual patient basis. Considering the high prevalence of substance abuse and addiction in the United States, involving consultants with addiction medicine expertise on perioperative teams may be a useful approach going forward.

In patients for whom the medication is discontinued preoperatively, it should be stopped 3 days before surgery. As long as the drug has been given sufficient time to be metabolized by the liver and excreted by the biliary system (typically 72 hours), mu-opioid agonists may be effectively used for postoperative analgesia, taking into account that most of these patients are opioid tolerant and require larger-than-standard doses. Although the duration of action for buprenorphine is about 40 hours, the elimination half-life after a sublingual dose is 37 hours. If buprenorphine-naloxone was given within the preceding 3 days before surgery, its effects may still be present as it has a very strong binding affinity for the mu-opioid receptor and dissociates very slowly from the receptor. If opioids are used for postoperative analgesia, the resulting analgesia may not be adequate using routine clinical doses if some of the buprenorphine is still present because of competitive binding of buprenorphine and its ceiling effect. Emphasis should be on regional anesthesia techniques and nonopioid agents, especially ketamine as a potent analgesic that does not affect respiratory drive and provides the most benefit after painful procedures.

For patients who continue taking buprenorphine-naloxone through the perioperative period, buprenorphine can provide sufficient and potent opioid analgesia as a partial mu-opioid agonist and for minor procedures may be adequate without much supplementation. For major surgery, however, additional analgesics will likely be needed. One investigator recommends the use of short-acting opioids, such as fentanyl, if a once-daily dosing regimen of buprenorphine-naloxone is continued perioperatively, though he noted that higher doses might be required. Additional doses of buprenorphine are often sufficient to manage pain within a multimodal analgesic regimen. Trying to overpower the effect of buprenorphine with other opioids may provide unpredictable results as well as unpredictable opioid side effects. For upper- or lower-extremity surgery, peripheral nerve blocks can often eliminate the need for supplemental opioids. A multimodal strategy will help minimize opioids. Early involvement by an APMS is recommended.
In the absence of definitive recommendations, the anesthesiologist will help decide whether to discontinue or continue the buprenorphine preoperatively, possibly in conjunction with the prescribing physician who should be involved with postdischarge planning and management. It cannot be emphasized enough how important collaboration and coordination are for safe and effective perioperative care of this complicated patient population.

**Naltrexone**

In contrast to buprenorphine or methadone, naltrexone is a full opioid competitive antagonist used in the treatment of opioid and alcohol addiction and is available as a once-daily oral agent or a monthly depot injection (Vivitrol). Overcoming the competitive blockade with opioid agonists to achieve analgesia requires markedly high doses of opioid medications and is not recommended. With the plasma half-life of oral naltrexone at 4 hours, and that of the active metabolite at 13 hours, patients should be advised not to take their once-daily dose on the morning of surgery. With the monthly depot injection, the antagonism lasts roughly 30 days; elective surgery should be delayed until at least 30 days after the last naltrexone injection if possible.

Patients treated for opioid addiction benefit from a preoperative plan regarding management of antagonist/mixed agents but may present for surgery, either emergently or having bypassed preoperative assessment, without such a plan. A careful discussion among patients, the anesthesiologist, and the surgical team is important, as opioids will be less effective or even ineffective in the setting of these agents. A decision will need to be made to proceed, maximizing nonopioid medications in a multimodal strategy, or to delay surgery.

The recommendations for managing postoperative analgesia for patients taking buprenorphine-naloxone through the perioperative period undergoing moderately or severely painful surgery are summarized as follows:

- Incorporate regional anesthesia techniques whenever possible.
- Administer nonopioid adjuncts unless contraindicated.
- If opioids are used, higher doses may be needed, the analgesic effect may be less, and the resulting side effects greater, justifying appropriately increased levels of monitoring.
- Consider involving an APMS early.

**Acute Pain Management Services in the Perioperative Surgical Home**

The postoperative period presents an excellent opportunity for an anesthesiologist-led APMS to actively help guide patients through hospitalization until discharge and beyond. Delivering patients safely through the intraoperative period is no longer sufficient. Adequate postoperative analgesia is a key area within the PSH that has an impact on long-term outcomes for patients. In the case of opioid-tolerant patients, the postoperative period is frequently the most challenging. Careful planning may yield significant improvements for these patients.

Continuous peripheral nerve blocks have continued to increase in popularity, especially in opioid-tolerant patients. The APMS has an important role in managing continuous peripheral nerve blocks and providing patient education. At the authors’ institution, the APMS physicians and colleagues skilled in regional anesthesia techniques work together to manage these patients who received a peripheral nerve block, including providing 24-hour coverage via a beeper that patients may call for problems or questions. Regional anesthesia and analgesic techniques will likely become even more important as their inclusion in surgical pathways increases.
A summary of the benefits of an APMS in the perioperative surgical home in the setting of opioid-tolerant patients in the postoperative period is as follows:

- Management of continuous peripheral nerve blocks, including titration, side effects, and ambulatory catheter instructions, from the recovery room until discharge and beyond
- Initiation and management of adjunctive medications, such as ketamine, that require expertise beyond the typical analgesic regimen
- Guidance and recommendations on opioid conversions and discharge regimens that include high opioid doses

**SUMMARY**

Management of acute pain with minimization of adverse events in opioid-tolerant patients undergoing surgery can be extremely challenging. The anesthesiologist, using his or her expertise in regional anesthesia techniques and pharmacology, can improve patient care within the PSH by implementing a comprehensive opioid-reducing strategy for opioid-tolerant patients that begins in the early preoperative period. Intraoperative care of these patients relies heavily on a multimodal analgesic regimen to minimize required opioids, and a postoperative APMS may help transition from the hospital setting to discharge. Anesthesiologists are expected to be involved in the entire perioperative process. Challenging patients, such as the opioid tolerant, demand our expertise, especially as the specialty of anesthesiology evolves to perioperative medicine.

For those practitioners working in institutions without discrete acute pain services or perioperative surgical home, a good place to start is to initiate discussions with the quality assessment and performance improvement team to bring these issues to the forefront. Interested practitioners can also approach their anesthesia and surgical colleagues to spark initiatives. Collaboration with anesthesia departments at other institutions that have implemented some elements of the PSH can be extremely helpful, especially with administrative or financial concerns. Changing institutional culture is difficult, and individual champions for improvement can be confronted by resentment if they take these issues on alone.

Future study will be needed to demonstrate the efficacy of the PSH, but the benefits seen by similar programs and the support of the ASA give optimism. The Triple Aim requires not only anesthesiologist expertise but also collaboration with physician colleagues and hospital administration. Through continued improvement measures, anesthesiologists are positioned to greatly improve the perioperative continuum.

**REFERENCES**


